Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy
Open Access
- 1 September 2020
- journal article
- research article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 15, 2207-2215
Abstract
Background: Adherence to inhaled maintenance therapy is critical to managing chronic obstructive pulmonary disease (COPD), while increasing rescue medication usage may indicate worsening symptoms. This study evaluated adherence and rescue medication use in patients with COPD without a history of exacerbation who initiated combination therapy with budesonide/formoterol (B/F) or umeclidinium/vilanterol (UMEC/VI). Methods: Retrospective observational study of commercially insured and Medicare Advantage with Part D enrollees who initiated UMEC/VI or B/F between January 1, 2014 and December 31, 2017 (earliest fill defined as index date). Eligibility criteria included age ≥ 40 years, 12 months continuous enrollment pre- and post-index, ≥ 1 pre-index COPD diagnosis, no pre-index asthma diagnosis, COPD-related exacerbations, or medication fills containing inhaled corticosteroids, long-acting β2-agonists, or long-acting muscarinic antagonists. Inverse probability of treatment weighting (IPTW) was used to balance treatment groups on potential confounders. Medication adherence (primary endpoint) was evaluated by the proportion of days covered (PDC). Rescue medication use (secondary endpoint) was standardized to canister equivalents (1 metered dose inhaler [200 puffs] or ∼ 100 nebulized doses of short-acting β2-agonist- and/or short-acting muscarinic agonist-containing medication). Results: After IPTW, covariates were balanced between cohorts (UMEC/VI: N=4082; B/F: N=9529). UMEC/VI initiators had a significantly greater mean PDC (UMEC/VI: 0.47 [0.33]; B/F: 0.38 [0.30]; P< 0.001) and significantly higher rates of adherence (PDC≥ 0.80) than B/F initiators (UMEC/VI: n=1004 [25%], B/F: n=1391 [15%]; relative risk: 1.68, 95% CI: 1.57, 1.81; P< 0.001). In the year following initiation, UMEC/VI initiators filled significantly fewer rescue medication canister equivalents than B/F initiators (predicted mean [95% CI]: 1.78 [1.69, 1.88] vs 2.15 [2.08, 2.23]; mean difference [95% CI]: − 0.37 [− 0.50, − 0.24]; P< 0.001), corresponding to 17% less (estimated) rescue medication use (incidence rate ratio [95% CI]: 0.83 [0.78, 0.88]). Conclusion: Among non-exacerbating patients with COPD initiating dual therapy, UMEC/VI demonstrated improved adherence and reduced rescue medication use compared with B/F.Keywords
This publication has 20 references indexed in Scilit:
- Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured PopulationJournal of Managed Care & Specialty Pharmacy, 2019
- Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysisRespiratory Research, 2017
- Overuse of short-acting beta-agonist bronchodilators in COPD during periods of clinical stabilityRespiratory Medicine, 2016
- Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims DataAnnals of the American Thoracic Society, 2016
- Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary diseaseBMC Pulmonary Medicine, 2015
- Effects of GOLD-Adherent Prescribing on COPD Symptom Burden, Exacerbations, and Health Care Utilization in a Real-World SettingChronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, 2015
- Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPDRespiratory Medicine, 2013
- Association of Chronic Obstructive Pulmonary Disease Maintenance Medication Adherence With All-Cause Hospitalization and Spending in a Medicare PopulationThe American Journal of Geriatric Pharmacotherapy, 2012
- Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costsRespiratory Medicine, 2010
- Medication adherence issues in patients treated for COPDInternational Journal of Chronic Obstructive Pulmonary Disease, 2008